ONCOLOGY Decoded

Experts detail presentations that may influence the standard of care across different bladder, kidney, and prostate cancer populations.

Experts review potential clinical advances highlighted at the 2026 ASCO Gastrointestinal Cancers Symposium.

Experts discuss how issues related to prostate cancer diagnoses and access to care differ across practices based in the US and India.

Experts cover the regulatory approvals and clinical trial readouts from 2025 that may move the needle for prostate cancer management.

Experts break down the clinical trial data and regulatory developments that made 2025 a “remarkable year” in kidney and bladder cancer management.

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Panelists and presenters attending World GU 2025 shared their perspectives on optimizing the management of prostate, kidney, and bladder cancers.

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.

Experts highlight methods for optimally treating patients with genitourinary cancers harboring variant histologies at World GU 2025.

At World GU 2025, experts discussed forming treatment strategies for patients with variant histologies across prostate, bladder, and kidney cancer.

Discover key takeaways on tumor markers, the BEP vs. EP debate, and the role of surgery in stage II testicular cancer.

Oncology Decoded provides the current management of metastatic bladder cancer, recent advancements in systemic therapy, patient selection, and AE mitigation.

The latest in first- and second-line therapies for bladder cancer, including trial data, AE management, and the role of molecular testing, were discussed in the latest Oncology Decoded podcast.

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.

Manojkumar Bupathi, MD, MS; and Benjamin Garmezy, MD, discuss abstracts from the 2025 ASCO Annual Meeting that may affect genitourinary cancer care.

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss abstracts from the 2025 ASCO Annual Meeting that may impact genitourinary cancer care.

Experts weigh in on the practical applications of PSMA PET imaging

Manojkumar Bupathi, MD, MS; Benjamin Garmezy, MD; Mike Lattanzi, MD, and x Damian N. Sorce, MD discuss how the practical applications of PSMA PET imaging, risk stratification, and evolving treatment strategies for advanced prostate cancer.

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.

Panelists discuss how upcoming studies at ASCO 2025 could change practice in kidney, bladder, and prostate cancer, highlighting research on novel drug combinations, biomarkers, organ-sparing approaches, and AI-driven treatment selection.